Abstract
Alzheimer’s disease (AD) is associated with insulin resistance and specific regional declines in cerebral metabolism. The effects of a novel mTOT modulating insulin sensitizer (MSDC-0160) were explored in non-diabetic patients with mild AD to determine whether treatment would impact glucose metabolism measured by FDG-PET in regions that decline in AD. MSDC-0160 (150 mg once daily; N=16) compared to placebo (N=13) for 12 weeks did not result in a significant difference in glucose metabolism in pre-defined regions when referenced to the pons or whole brain. However, glucose metabolism referenced to cerebellum was maintained in MSDC-0160 treated participants while it significantly declined for placebo patients in anterior and posterior cingulate, and parietal, lateral temporal, medial temporal cortices. Voxel-based analyses showed additional differences in FDG-PET related to MSDC-0160 treatment. These exploratory results suggest central effects of MSDC-0160 and provide a basis for further investigation of mTOT modulating insulin sensitizers in AD patients.
Keywords: Alzheimer’s disease, FDG-PET, insulin resistance, insulin sensitizer, mTOT modulator.
Current Alzheimer Research
Title:An Evaluation of MSDC-0160, A Prototype mTOT Modulating Insulin Sensitizer, in Patients with Mild Alzheimer's Disease
Volume: 11 Issue: 6
Author(s): Raj C. Shah, Dawn C. Matthews, Randolph D. Andrews, Ana W. Capuano, Debra A. Fleischman, James T. VanderLugt and Jerry R. Colca
Affiliation:
Keywords: Alzheimer’s disease, FDG-PET, insulin resistance, insulin sensitizer, mTOT modulator.
Abstract: Alzheimer’s disease (AD) is associated with insulin resistance and specific regional declines in cerebral metabolism. The effects of a novel mTOT modulating insulin sensitizer (MSDC-0160) were explored in non-diabetic patients with mild AD to determine whether treatment would impact glucose metabolism measured by FDG-PET in regions that decline in AD. MSDC-0160 (150 mg once daily; N=16) compared to placebo (N=13) for 12 weeks did not result in a significant difference in glucose metabolism in pre-defined regions when referenced to the pons or whole brain. However, glucose metabolism referenced to cerebellum was maintained in MSDC-0160 treated participants while it significantly declined for placebo patients in anterior and posterior cingulate, and parietal, lateral temporal, medial temporal cortices. Voxel-based analyses showed additional differences in FDG-PET related to MSDC-0160 treatment. These exploratory results suggest central effects of MSDC-0160 and provide a basis for further investigation of mTOT modulating insulin sensitizers in AD patients.
Export Options
About this article
Cite this article as:
Shah C. Raj, Matthews C. Dawn, Andrews D. Randolph, Capuano W. Ana, Fleischman A. Debra, VanderLugt T. James and Colca R. Jerry, An Evaluation of MSDC-0160, A Prototype mTOT Modulating Insulin Sensitizer, in Patients with Mild Alzheimer's Disease, Current Alzheimer Research 2014; 11 (6) . https://dx.doi.org/10.2174/1567205011666140616113406
DOI https://dx.doi.org/10.2174/1567205011666140616113406 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cutaneous Lupus Erythematosus in Children
Current Pediatric Reviews Stereoselective Synthesis and Antiproliferative Activity of Monoterpene-Fused 2- Imino-1,3-oxazines
Current Organic Synthesis Renal Heat Shock Proteins Over-Expression Due to Anabolic Androgenic Steroids Abuse
Mini-Reviews in Medicinal Chemistry Transcriptional Regulation of the Heme Oxygenase-1 Gene Via the Stress Response Element Pathway
Current Pharmaceutical Design Research on Monitoring System of Daily Statistical Indexes Through Big Data
Recent Advances in Computer Science and Communications Strategies to Improve Bioavailability and <i>In Vivo</i> Efficacy of the Endogenous Opioid Peptides Endomorphin-1 and Endomorphin-2
Current Topics in Medicinal Chemistry Editorial [Hot Topic:Gamma-Secretase Inhibitors and Modulators as a Therapeutic Approach to Alzheimers disease (Guest Editor: Bruno P. Imbimbo)]
Current Topics in Medicinal Chemistry Proteomic Strategies for the Analysis of Carbonyl Groups on Proteins
Current Protein & Peptide Science Strategic Paradigm Shifts in the Antimicrobial Drug Discovery Process of the 21st Century
Infectious Disorders - Drug Targets Increased Susceptibility to Oxidative Death of Lymphocytes from Alzheimer Patients Correlates with Dementia Severity
Current Alzheimer Research Protease Inhibitors with Antileishmanial Activity
Current Enzyme Inhibition Novel AβIsoforms in Alzheimer's Disease - Their Role in Diagnosis and Treatment
Current Pharmaceutical Design A Case of Topiramate-Induced Epistaxis
Current Drug Safety Formulation Approaches of Triptans for Management of Migraine
Current Drug Delivery Neurotoxic Aβ: Linking Extracellular and Intracellular Aβ in Alzheimer’s Disease
Current Protein & Peptide Science Once-a-Day (QD) vs Twice-Daily (BID) Nevirapine as Simplification in PITreated Patients After 2 mos. of BID Induction
Current HIV Research Coumarin: A Promising Scaffold for Design and Development of Bioactive Agents
Current Bioactive Compounds Preface
Current Pharmaceutical Design Immunomodulatory Drugs (IMiDs) in Multiple Myeloma
Current Cancer Drug Targets Natural Carriers for siRNA Delivery
Current Pharmaceutical Design